Zacks Research Analysts Boost Earnings Estimates for Masimo

Masimo Co. (NASDAQ:MASI) – Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Masimo in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical equipment provider will post earnings of $0.91 per share for the quarter, up from their prior estimate of $0.89. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q3 2025 earnings at $1.01 EPS, Q4 2025 earnings at $1.34 EPS, FY2025 earnings at $4.25 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.45 EPS and FY2026 earnings at $4.89 EPS.

A number of other brokerages have also issued reports on MASI. Wells Fargo & Company boosted their price target on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler boosted their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $191.40.

Masimo Trading Down 4.1 %

Shares of MASI stock opened at $169.96 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 1 year low of $101.61 and a 1 year high of $184.51. The stock has a fifty day moving average of $172.90 and a two-hundred day moving average of $151.29. The firm has a market capitalization of $9.10 billion, a PE ratio of 117.21 and a beta of 1.02.

Institutional Investors Weigh In On Masimo

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC raised its position in shares of Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 60 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. raised its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Masimo by 0.8% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after purchasing an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in shares of Masimo by 0.8% during the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after purchasing an additional 83 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.